Nick Paul Taylor

Biography for Nick Paul Taylor

Nick Taylor, UK Correspondent

Nick Taylor is a freelance journalist with more than six years' experience of reporting on the global biopharma industry. Since graduating with a biology degree from the University of York, Nick has written for numerous healthcare publications, including Nature BioPharma Dealmakers, Life Science Leader and Outsourcing-Pharma. You can contact him at ntaylor@fiercemarkets.com and follow him on Twitter at @NickPaulTaylor.

Articles by Nick Paul Taylor

PaxVax raises $22M for PhIII trial of cholera vaccine

PaxVax has raised $22 million in venture capital funding to advance development of its oral cholera vaccine, PXVX0200. The investment gives PaxVax the cash to run a 3,000-patient Phase III trial of the product.

CDC considers expanding use of Bexsero as meningitis outbreak spreads

Princeton University will not begin to offer Novartis' meningitis B vaccine to Bexsero to students until next week, but health officials are already considering expanding the campaign to another university. An outbreak at the University of California, Santa Barbara, is the cause of the latest concerns.

TB vaccine shows promise in preventing MS

A lack of exposure to infections early in life is one of many proposed contributing factors to development of multiple sclerosis. With this in mind, some have questioned whether giving the immune system a light workout could stave off the autoimmune disorder. 

FDA animal study: Whooping cough vaccine fails to stop the disease's spread

For most of the second half of the 20th century, whooping cough was a disease of the past, one of many previously common infections practically eliminated by vaccines. Since the 1980s the bacteria has fought back though, and now FDA researchers have a theory why--vaccines might not be stopping transmission.

A California nonprofit is crowdfunding its tech-enabled HIV vaccine project

In the 25 years since the first World AIDS Day, patient outcomes have improved significantly, but the long-sought-after vaccine remains elusive. As the world commemorated the event this week, two very different projects outlined their plans to combat the virus.

The argument for vaccinating: 100M cases of disease prevented in U.S.

For many people, vaccines trail only clean water on the list of interventions that have had the biggest effect on infectious diseases. Yet with many others fiercely opposed to vaccines, data is needed to support the argument. This week the data arrived, and it makes a strong case for the importance of vaccines.

GAVI adds support for inactivated polio vaccine

The GAVI Alliance is adding the inactivated poliovirus vaccine (IPV) to the list of products it makes available for routine immunization in the world's 73 poorest countries. GAVI is encouraging countries to co-finance IPV but not making it mandatory.

Value of Pentagon-backed vaccine plant questioned

While few question the necessity of the Defense Department's investments in protecting military personnel from biological threats, the scale and type of projects is a source of considerable controversy, as shown by the Pentagon's latest push into vaccine manufacturing.

Sanofi hunting for bolt-on vaccine deals

At a time when its Big Pharma peers have sold noncore assets, Sanofi has diversified, with multibillion-dollar acquisitions of Genzyme and Merial adding biotech and animal health assets, respectively. Now, CEO Chris Viehbacher is looking for smaller, bolt-on deals to boost the vaccine business.

Ranbaxy reportedly ready to sell vaccine unit

When Ranbaxy bought vaccine supplier Biovel in 2010, the then-CEO of the beleaguered Indian generic firm called it an important part of the company's growth strategy. The CEO is long gone, having resigned within months of buying Biovel, and now Ranbaxy is reportedly ready to split up with its vaccine unit too.